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Abstract 
Mass spectrometry has been applied to determine the deamidation sites and the 
aggregation region of the deamidated human islet amyloid polypeptide (hIAPP).  
Mutant hIAPP with iso-aspartic residue mutations at possible deamidation sites showed 
very different fibril formation behavior, which correlates with the observed 
deamidation-induced acceleration of hIAPP aggregation. 
 
 
Deamidation is a non-enzymatic post-translational modification (PTM) which 
contributes to protein ageing.1  Deamidation occurs spontaneously in solution at 
asparagine (Asn) and glutamine (Gln) residues, and results in formation of iso-aspartic 
acid/aspartic acid and γ-glutamic acid/glutamic acid (and their stereoisomers), 
respectively.2, 3  The deamidation rate of Asn is faster than Gln due to the shorter 
distance between the main chain amido group (-NH-) and the side chain amide group 
(-NH2-).
4, 5  With an additional methylene group (-CH2-) into the backbone of iso-
aspartic acid and γ-glutamic acid; the tertiary structure, stability, folding, and function 
of proteins can be dramatically altered by deamidation.6, 7  Previous studies showed 
that deamidation can accelerate fibril formation in certain cases, including mutated 
amyloid-β (D7N and D23N) observed in Alzheimer’s disease.8, 9  Aggregation of β2-
microglobulin from dialysis-associated amyloidosis disease,10, 11 and αB-crystallin 
from human eye lens have also been shown to be affected by deamidation.12, 13 
 Human islet amyloid polypeptide (hIAPP; also referred to as amylin) is a 37-
residue hormone peptide co-secreted with insulin and involved in regulating blood 
glucose levels.14  The concentration of hIAPP is around 1-2% relative to the level of 
insulin in secretory granules.15  hIAPP contains an intramolecular disulfide bond 
between Cys-2 and Cys-7, as well as an amidated C-terminus,16 and is an intrinsically 
disordered protein with a low level of persistent helical structure between residues Asn-
3 and Leu-27 in solution.17  hIAPP is an amyloid protein which contains six Asn and 
one Gln as potential deamidation sites.  A previous study from Nilsson et al. used a 
variant of hIAPP segment, residues 20-29 (SNNFPAILSS) which is non-amyloidogenic 
and showed that addition of less than 5% of deamidated monomer could accelerate the 
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amyloid fibril formation.18  Results from Dunkelberger et al. also showed that 
deamidation of hIAPP disrupted the β-sheet structure around Leu-27, resulting in a 
morphology change of hIAPP fibrils, along with accelerated fibril formation.19  The 
formation of hIAPP fibrils does not contribute to type II diabetes (T2D); however early 
oligomers of hIAPP lead to the decline of pancreatic β-cell mass and the failure of islet 
cell transplantation for T2D treatment.20-22  Thus, accelerating the formation of the 
early oligomers of hIAPP may reduce the graft survival rate.17, 23  Deamidation has a 
significant impact on hIAPP fibril formation,24, 25 the effects on the deamidation rate, 
the deamidation site(s), and the effects of isomeric deamidation products of hIAPP, 
however, have not yet been fully addressed. 
 MS is a powerful tool for examining deamidation in proteins as the deamidation 
reaction produces products with a mass shift of +0.984 Da (-NH2 to -OH) at the 
deamidated residue, which is readily detected by MS.26-28  Previous studies also 
suggested that deamidation can be directly quantified by measuring the peak area of the 
non-deamidated and deamidated peaks, thus the percentage of deamidation in the 
sample can be estimated.29, 30  Tandem MS/MS can further locate the deamidation site 
in proteins, and differentiate the isomeric deamidation products.2, 26-30  Collisionally 
activated dissociation (CAD) MS/MS can localise deamidation site via a mass shift 
(+0.984 Da) appears in b and y ion fragments containing the deamidated residue, while 
unmodified fragments are observed in the regions not containing deamidated residues.30  
Electron capture dissociation (ECD) MS/MS can be used to not only localises the 
deamidation site in protein, but also uses to differentiate the isomeric products of 
deamidation by the mass shift of +58 and -57 Da at the c and z ion fragments of iso-/γ- 
deamidation products respectively.  The peak intensity of iso-/γ- deamidation products 
can also compare with the peak intensity of aspartic acid/glutamic acid in order to 
determine the ratio of the isomeric products.29 
 In order to localise the deamidation site(s) in the incubated hIAPP solution, CAD 
MS/MS with a 12 Tesla (T) Fourier transform ion cyclotron mass spectrometer (FTICR 
MS) was applied.  The y5 fragment clearly showed a deamidated peak in the incubated 
sample (Fig. 1B), indicating deamidation occurs at Asn-35 residue in hIAPP.  For the 
b fragments, no deamidated peaks were observed for the first 20 amino acid residues 
(Fig. 1C); however, a deamidated peak was present corresponding to the b21 fragment 
(Fig. 1D), suggesting deamidation only occurs at Asn-21 but not at Asn-3, Gln-10, and 
Asn-14 residues.  Furthermore, another deamidated peak was detected corresponding 
to the b22 fragment ion in the incubated solution (Fig. 1E), indicating Asn-22 also 
deamidates within four weeks at 37oC. 
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Figure 1. (A) The amino acid sequence of hIAPP. The potential deamidation sites are coloured in red. 
Key CAD MS/MS fragments of hIAPP revealing deamidation at amino acid residues after 4 weeks 
incubation at 37oC are shown (B) y5, (C) b20, (D) b21, and (E) b22. The blue/red circles indicate the isotopic 
peaks of singly/doubly deamidated fragments, respectively. 
 
 Subsequently, MS was applied to determine the deamidation rates of each 
individual deamidated site in the incubated solutions and resulting fibrils by calculating 
the percentage ratio between the non-deamidated and the deamidated fragment ion peak 
areas for each sample.  In the incubated solution, the earliest deamidation instance was 
observed on day 5, and was identified within the y5 fragment ion (Fig. 2A), indicating 
the Asn-35 is the first amino acid residue in hIAPP to undergo deamidation, which 
requires 5-day of incubation at 37oC.  Deamidation at the b21 and b22 fragment ions 
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was observed on day 8, suggesting Asn-21 and Asn-22 residues are the next amino acid 
residue to deamidate in hIAPP and require a longer incubation time for deamidation 
compared to Asn-35 residue.  Though the extent of deamidation increased with the 
incubation time; a similar percentage and rate of deamidation were found in the y5, b21, 
and b22 fragment ions at the various time points for the incubated solutions.  After 28 
days incubation, each deamidated fragment ion (y5, b21, and b22) of the soluble hIAPP 
showed ~18% deamidation, indicating even though the initial deamidation time 
between Asn-21, Asn-22, and Asn-35 residues are different, the extent as well as the 
rate of deamidation of these residues are similar across and at the end of the incubation 
time.  The insoluble protein pellets formed over the course of the incubation were re-
solubilised and showed a greater extent of deamidation than the soluble hIAPP species.  
Deamidation was observed in the day-7, day-14, day-21, and day-28 samples (Fig. 2B).  
On day-7, ~7.5% of the y5 fragment ion was deamidated while no deamidation was 
observed for the b21 and b22 fragment ions in the pellet.  On day-14, the extent of 
deamidation for the y5 fragment ion increased sharply to 16% and the b21 and b22 
showed ~7.5% deamidation.  After 28 days incubation, the extent of deamidation of 
the y5, b21, and b22 fragment ions were at 39%, 30%, and 29% respectively, distinctly 
larger than for the soluble hIAPP species above, suggesting the fibrils of hIAPP contains 
a higher extent of deamidation at Asn-35 compared to Asn-21 and Asn-22 residues.  
The residue Asn-35 was the earliest deamidation site observed in the incubated 
solutions and contained the highest extent of deamidation in the fibril pellets, which 
agrees with the findings in previous deamidation studies,3, 31 suggesting that the primary 
sequence of Ser-35Asn-Thr in hIAPP had the shortest deamidation time among all the 
other segments studied.  The higher extent of deamidation observed in the fibrils of 
hIAPP compared to the incubated solutions also indicates that deamidated hIAPP tends 
to aggregate and form insoluble fibrils more rapidly than the wild-type hIAPP. 
 
Figure 2. The extent of deamidation observed in CAD MS/MS fragments; the y5 (black), b21 (red), and 
b22 (blue) for 10 μM aqueous hIAPP (A) solutions and (B) dissolved fibril solutions. 
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 In order to ascertain the effects of deamidated isomeric products on the 
aggregation process, pure mutant hIAPP peptides were synthesised with aspartic acid 
((D)3hIAPP) or iso-aspartic acid ((isoD)3hIAPP) replacement at the detected 
deamidation site from above, i.e. residues 21, 22, and 35 (Fig. S1, ESI†).  The 7+ 
charge state dimers of ((D)3hIAPP) and ((isoD)3hIAPP) were fragmented by ECD 
MS/MS in order to determine the non-covalent interaction region between the mutant 
hIAPP units (Fig. S2 – S3, ESI†).  The aggregation regions of ((D)3hIAPP) and 
((isoD)3hIAPP) were found between Asn-31 and Thr-36 residues, which is similar to 
the proposed aggregation region of 7+ charge state dimer of wild-type hIAPP in the 
previous studies, suggesting there is no difference between the wild-type and the two 
mutant hIAPPs regarding the aggregation sites for the formation of early oligomers.32   
 MS can quantify soluble amyloid proteins in solution.32  The ionisation of 
aqueous protein solutions to gas phase ions, however, is limited to soluble components 
only, so that the insoluble fibrils are difficult to quantify using MS.  Thus, the relative 
concentration of amyloid fibrils formed in the incubated solutions were determined by 
using Thioflavin T (ThT) fluorescence emission analysis at the wavelength of 490 nm 
and the overall structures of fibrils were observed using transmission electron 
microscopy (TEM).  The relative fluorescence emission of the 10 μM solutions of 
wild-type hIAPP, ((D)3hIAPP), and ((isoD)3hIAPP) were measured and the lag phases 
of the formation of mature fibrils in wild-type hIAPP solution was 42 hours while in 
((D)3hIAPP) and ((isoD)3hIAPP) solutions were ~ 30 hours (Fig. 3A – 3C), indicating 
mutant hIAPPs with deamidated residues replacement at Asn-21, Asn-22, and Asn-35 
accelerate the rate of mature fibrils formation which supports the hypothesis that 
deamidated hIAPPs accelerate the aggregation rate of non-deamidated hIAPP.18, 19  
TEM images of the wild-type hIAPP, ((D)3hIAPP), and ((isoD)3hIAPP) solutions 
incubated at 37oC for one week were also obtained (Fig. 3E – 3G).  Branched and 
elongated fibrils were observed in the wild-type hIAPP as well as ((D)3hIAPP) 
incubated solutions; while densely packed fibrils were found in ((isoD)3hIAPP) 
solution.  The fibril structures observed in ((isoD)3hIAPP) solution were distinctly 
different from the fibrils found in wild-type hIAPP and ((D)3hIAPP), suggesting the 
morphology of fibrils formed in ((isoD)3hIAPP) is different from wild-type hIAPP as 
well as ((D)3hIAPP). 
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Figure 3.  The relative fluorescence activity of the incubated 10 μM (A) ThT solution (control; black), 
10 μM wild-type hIAPP (blue), (B) 10 μM mutant ((D)3hIAPP) (green), and (C) 10 μM mutant 
((isoD)3hIAPP) (red) solutions measured at emission 490 nm.  The TEM images of the (D) fresh and 
(E) 1-week incubated 10 μM wild-type hIAPP solutions. The TEM images of 10 μM (F) ((D)3hIAPP) 
and (G) ((isoD)3hIAPP) solutions after 1 week incubation at 37oC.  The scale bars for each TEM image 
are inset. 
 
 In order to study the effects of the isomeric deamidation products on the wild-type 
hIAPP aggregation, ((D)3hIAPP) and ((isoD)3hIAPP) solutions were individually 
spiked into wild-type hIAPP solution at 5%, 10%, 25%, and 50% amounts.  After one 
week incubation, the percentage of remaining soluble monomeric hIAPP in the seeded 
solutions was consistently less in the spiked solutions than the control hIAPP incubated 
solution, and less soluble hIAPP was found in the mutant ((isoD)3hIAPP) spiked 
solutions compared to the ((D)3hIAPP) spiked solutions (Fig. 4A).  The p-values of 
seeding 5% and 10% mutant ((D)3hIAPP) into the solution were higher than 0.05, which 
indicated the differences between the seeded solutions and the control sample were not 
significant.  The p-values of the remaining seeded solutions were less than 0.05, which 
showed significant differences between the control and the seeded solutions.  The 
normalised percentage of soluble hIAPP with 5% spiking of ((D)3hIAPP) or 
((isoD)3hIAPP) was 4% and 9% less than the soluble hIAPP found in the control 
incubated solutions respectively.  The normalised percentage of soluble hIAPP 
consistently decreased with increased amounts of ((D)3hIAPP) or ((isoD)3hIAPP) in the 
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incubated solutions.  For the solutions with 50% spiking of ((D)3hIAPP) or 
((isoD)3hIAPP), the normalised percentage of soluble hIAPP was 28% and 46% less 
than the soluble hIAPP found in the control solutions respectively.  These results 
indicate the effects of mutant hIAPPs in accelerating wild-type hIAPP are 
concentration-dependent. 
 
Figure 4.  (A) A plot showing the normalised percentage of soluble hIAPP in the 10 μM solutions with 
spiking different percentage of mutant ((D)3hIAPP) or ((isoD)3hIAPP) to wild-type hIAPP (control) 
measured using MS after 1 week incubation.  * indicates the p-value of the sample percentages are less 
than 0.05 compared to the control percentage in a paired t-test.  (D) The relative fluorescence activity 
of 10 μM hIAPP, 9.5 μM hIAPP plus 0.5 μM (5%) ((D)3hIAPP), and 9.5 μM hIAPP plus 0.5 μM (5%) 
((isoD)3hIAPP) measured at emission 490 nm.   
 
 The fibrils formed during the incubation experiments were measured using ThT 
fluorescence spectroscopy.  The measured percentage change of fluorescence 
emission in 5% mutant hIAPP seeded solutions further indicated that the amount of 
amyloid fibrils formed in the seeded solutions were consistently higher than the wild-
type hIAPP incubated solution and the overall percentage of amyloid fibrils formed in 
((D)3hIAPP) and ((isoD)3hIAPP) seeded solutions was 27% and 48% higher than the 
wild-type hIAPP incubated solution respectively (Fig. 4B).  The fluorescence 
emission measurement and MS quantification showed the effect of seeding 
((isoD)3hIAPP) is twice that of seeding the same amount of ((D)3hIAPP) into non-
deamidated hIAPP solutions.  The difference between the TEM images of incubated 
((D)3hIAPP) and ((isoD)3hIAPP) solutions also agrees the greater effect of 
((isoD)3hIAPP) compared to ((D)3hIAPP) (Fig. 3E – 3G).  The observed morphology 
of fibrils was different in ((isoD)3hIAPP) compared to ((D)3hIAPP), indicating 
differences in the aggregation behaviour and rate of non-deamidated hIAPP, as 
observed in the MS and fluorescence. 
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 In order to examine the effects of mutant ((D)3hIAPP) and ((isoD)3hIAPP) in 
incubated solutions and fibrillary pellets, MS spectra of mixed wild-type hIAPP with 
various spiking percentage of mutant ((D)3hIAPP) and ((isoD)3hIAPP) were acquired 
(Fig. S4, ESI†).  The peak intensity of mutant ((D)3hIAPP) and ((isoD)3hIAPP) were 
consistently higher in the fibrillary pellets compared to the incubated and the fresh 
solutions, suggesting the important role of ((D)3hIAPP) or ((isoD)3hIAPP) in enhancing 
fibril formation.  
 The experimental results herein demonstrate the importance as well as the effects 
of hIAPP deamidation on hIAPP aggregation rate.  Deamidation of hIAPP is shown to 
occur at Asn-21, Asn-22, as well as Asn-35 residues of the incubation and a higher 
percentage of deamidated hIAPP was observed in fibrillary pellet, suggesting that 
deamidated hIAPP can accelerate the rate of hIAPP fibril formation.  The 
experimental results of the mutant hIAPP, ((D)3hIAPP) and ((isoD)3hIAPP), not only 
agree with the hypothesis of deamidated hIAPP can increase fibril formation, but also 
suggest the effect of seeding ((isoD)3hIAPP) is twice than that of ((D)3hIAPP) seeding 
into non-deamidated hIAPP solutions as the morphology of ((isoD)3hIAPP) fibrils are 
distinctly different from the fibrils formed in ((D)3hIAPP) solutions.  These results 
provide qualitative and quantitative evaluation of deamidated hIAPP on the rate of 
aggregation which could help inform further studies of the effects of deamidation on 
accelerating amyloid fibril formation.  
 
Conflicts of interest 
There are no conflicts to declare. 
 
Acknowledgements 
This research was supported by the funding from University of Warwick Research 
Development Fund (RD16003), Engineering and Physical Sciences Research Council 
(EP/F034210/1, EP/J000302/1, EP/N021630/1), Funds for Women Graduates, and 
Great Britain China Centre. 
 
References 
1. E. R. Stadtman, J. Gerontol., 1988, 43, B112-B120. 
2. J. J. Cournoyer, J. L. Pittman, V. B. Ivleva, E. Fallows, L. Waskell, C. E. 
Costello and P. B. O'Connor, Protein Sci., 2005, 14, 452-463. 
3. N. E. Robinson and A. B. Robinson, Proc. Natl. Acad. Sci. USA, 2001, 98, 944-
949. 
4. A. B. Robinson and C. J. Rudd, Curr. Top. Cell. Regul., 1974, 8, 247-295. 
5. H. T. Wright, Crit. Rev. Biochem. Mol. Biol., 1990, 26, 1-52. 
9 
 
6. H. A. Doyle and M. J. Mamula, Trends Immunol., 2001, 22, 443-449. 
7. N. E. Robinson and A. Robinson, Molecular clocks: deamidation of asparaginyl 
and glutaminyl residues in peptides and proteins, Althouse press, Oregon, 2004. 
8. N. P. Sargaeva, C. Lin and P. B. O'Connor, Anal. Chem., 2011, 83, 6675-6682. 
9. T. Shimizu, H. Fukuda, S. Murayama, N. Izumiyama and T. Shirasawa, J. 
Neurosci. Res., 2002, 70, 451-461. 
10. N. M. Kad, N. H. Thomson, D. P. Smith, D. A. Smith and S. E. Radford, J. Mol. 
Biol., 2001, 313, 559-571. 
11. A. J. Soulby, J. W. Heal, M. P. Barrow, R. A. Roemer and P. B. O'Connor, 
Protein Sci., 2015, 24, 850-860. 
12. R. Gupta and O. P. Srivastava, Invest. Ophthalmol. Vis. Sci., 2004, 45, 206-214. 
13. T. Takata, J. T. Oxford, B. Demeler and K. J. Lampi, Protein Sci., 2008, 17, 
1565-1575. 
14. G. J. S. Cooper, A. J. Day, A. C. Willis, A. N. Roberts, K. B. M. Reid and B. 
Leighton, Biochim. Biophys. Acta, 1989, 1014, 247-258. 
15. E. Jaikaran, M. R. Nilsson and A. Clark, Biochem. J, 2004, 377, 709-716. 
16. S. Luca, W. M. Yau, R. Leapman and R. Tycko, J. Biochem., 2007, 46, 13505-
13522. 
17. G. T. Westermark, P. Westermark, C. Berne, O. Korsgren and T. Nordic Network 
Clin Islet, New Engl. J. Med., 2008, 359, 977-979. 
18. M. R. Nilsson, M. Driscoll and D. P. Raleigh, Protein Sci., 2002, 11, 342-349. 
19. E. B. Dunkelberger, L. E. Buchanan, P. Marek, P. Cao, D. P. Raleigh and M. T. 
Zanni, J. Am. Chem. Soc., 2012, 134, 12658-12667. 
20. L. Haataja, T. Gurlo, C. J. Huang and P. C. Butler, Endocr. Rev., 2008, 29, 303-
316. 
21. A. Clark, C. Wells, I. Buley, J. Cruickshank, R. Vanhegan, D. Matthews, G. 
Cooper, R. Holman and R. Turner, Diabetes research (Edinburgh, Scotland), 
1988, 9, 151-159. 
22. A. Lorenzo, B. Razzaboni, G. C. Weir and B. A. Yankner, Nature, 1994, 368, 
756-760. 
23. K. Potter, A. Abedini, P. Marek, A. Klimek, S. Butterworth, M. Driscoll, R. 
Baker, M. Nilsson, G. Warnock and J. Oberholzer, Proc. Natl. Acad. Sci. USA, 
2010, 107, 4305-4310. 
24. P. T. Nguyen, X. Zottig, M. Sebastiao and S. Bourgault, J. Biochem., 2017, 56, 
3808-3817. 
25. R. Akter, P. Cao, H. Noor, Z. Ridgway, L. H. Tu, H. Wang, A. G. Wong, X. X. 
Zhang, A. Abedini, A. M. Schmidt and D. P. Raleigh, J. Diabetes Res., 2016, 
DOI: 10.1155/2016/2798269, 18. 
10 
 
26. W. Y. K. Chan, T. D. Chan and P. B. O'Connor, J. Am. Soc. Mass. Spectrom., 
2010, 21, 1012-1015. 
27. P. P. Hurtado and P. B. O'Connor, Anal. Chem., 2012, 84, 3017-3025. 
28. X. Li, X. Yu, C. E. Costello, C. Lin and P. B. O'Connor, Anal. Chem., 2012, 84, 
6150-6157. 
29. J. J. Cournoyer, C. Lin, M. J. Bowman and P. B. O'Connor, J. Am. Soc. Mass. 
Spectrom., 2007, 18, 48-56. 
30. H. Yang and R. A. Zubarev, Electrophoresis, 2010, 31, 1764-1772. 
31. N. E. Robinson and A. B. Robinson, Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 
4367-4372. 
32. Y. P. Y. Lam, C. A. Wootton, I. Hands-Portman, J. Wei, C. K. C. Chiu, I. 
Romero-Canelon, F. Lermyte, M. P. Barrow and P. B. O’Connor, Anal. Chem., 
2018, Submitted. 
33. P. Caravatti and M. Allemann, Org. Mass Spectrom., 1991, 26, 514-518. 
34. F. T. S. Chan, G. S. K. Schierle, J. R. Kumita, C. W. Bertoncini, C. M. Dobson 
and C. F. Kaminski, Analyst, 2013, 138, 2156-2162. 
35. T. Yang, X. H. Wang, C. L. Zhang, X. Ma, K. Wang, Y. Q. Wang, J. Luo, L. 
Yang, C. Yao and X. Y. Wang, Chem. Commun., 2016, 52, 2245-2248. 
 
  
11 
 
 
Graphic Abstracts: 
 
Deamidation sites of hIAPP were determined and the amount of fibril formed in mutant 
hIAPPs were higher than wild-type hIAPP. 
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Electronic Supplementary Information 
Experimental Procedure 
Sample preparation for deamidated hIAPP and fibrils.  Wild-type hIAPP 
lyophilized powder (Sigma Aldrich Company Ltd, Dorset, England) was dissolved in 
Milli-Q (Direct-Q® 3 UV System, Millipore Corporation, US) H2O (~pH 7.5) at a 
concentration of 500 µM and further diluted into 10 uM solution. The 10 µM hIAPP 
aqueous solution was incubated for 28 days (4 weeks).  The incubated solution was 
then centrifuged at 14,000 rpm for one hour to separate the soluble hIAPP (supernatant) 
from the insoluble hIAPP fibril (fibrillary pellet).  The supernatant solution containing 
soluble hIAPP was then diluted 20-fold with 49.5:49.5:1 water/acetonitrile/formic acid 
prior to MS analysis. hIAPP fibrillary pellets from 7-, 14-, 21-, and 28-day solutions 
were rinsed with 100 μL Milli-Q H2O three times and then re-dissolved with 20 µL of 
47.5:47.5:5 water/acetonitrile/formic acid, and sonicated in water bath at 37 oC for one 
hour.  Re-dissolved samples were further diluted with 80 µL of 50:50 
water/acetonitrile. The final concentration of formic acid in solutions was 1% 
(mol/mol). 
 
Sample preparation for seeding mutant peptides.  Wild-type hIAPP lyophilized 
powder and synthetic mutant hIAPPs (Pepscan Company Ltd, The Netherlands) were 
dissolved in Milli-Q H2O to a concentration of 500 µM.  The seeding experiments 
were performed by mixing wild-type hIAPP stock solution with 5%, 10%, 25%, or 50% 
mutant ((D)3hIAPP) or ((isoD)3hIAPP) solutions.  Samples were then diluted to a final 
concentration of 10 µM wild-type hIAPP plus mutant ((D)3hIAPP) or ((isoD)3hIAPP), 
which were incubated for 1 week at 37oC.  The supernatants and fibrillary pellets were 
separated and prepared as mentioned above. 
 
FTICR MS analysis.  Mass spectra were acquired on a 12 tesla solariX FTICR MS 
(Bruker Daltonik GmbH, Bremen, Germany).  All samples were analyzed in positive 
ionization mode.  For the detection of deamidated hIAPP and dissociated fibrils, an 
Apollo II electrospray ionization (ESI) source (Bruker Daltonik GmbH, Bremen, 
Germany) was used with a capillary voltage of 4-4.5 kV.  The ESI flow rate was 
optimized to 100-150 µL/h and the source temperature was set to 200oC.  Ions were 
externally accumulated in a hexapole collision cell before transferred to an infinity cell 
(ICR cell) for excitation and detection.33  Data obtained from FTICR-MS were 
analyzed using Bruker DataAnalysis 4.2 software (Bruker Daltonics, Bremen, 
Germany).  For the CAD experiments, precursor ions were first isolated using the 
quadrupole mass filter, then collided with argon gas and accumulated in the collision 
cell.  The collision energy was optimized to 2-18 V and the ion accumulation time to 
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1-3 seconds.  Fragments were then transferred to the infinity cell for detection.  The 
most intense isotopic peak from each fragment with signal-to-noise ratio (S/N) over 5 
was manually matched with the theoretical m/z.  All of the fragments were internally 
calibrated and then assigned with an uncertainty less than 1 part-per-million (ppm). 
 
Quantification of deamidated/ mutant hIAPP in solutions and fibrillary pellets.  
The monoisotopic peak area of non-deamidated and deamidated/mutant hIAPP peaks 
were measured using Bruker DataAnalysis 4.2 software.  The percentage of 
deamidated hIAPP (%) was calculated as follows:  
Deamidated (%) =
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑑𝑒𝑎𝑚𝑖𝑑𝑎𝑡𝑒𝑑 ℎ𝐼𝐴𝑃𝑃
𝑆𝑢𝑚 𝑜𝑓 𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑑𝑒𝑎𝑚𝑖𝑑𝑎𝑡𝑒𝑑 ℎ𝐼𝐴𝑃𝑃 𝑎𝑛𝑑 𝑛𝑜𝑛𝑑𝑒𝑎𝑚𝑖𝑑𝑎𝑡𝑒𝑑 ℎ𝐼𝐴𝑃𝑃
 𝑥 100% 
The same calculation method was applied to obtain the percentage of mutant hIAPP 
against wild-type hIAPP.  
 
Transmission electron microscopy (TEM).  The TEM images of the incubated 
solutions, including 10 µM wild-type hIAPP, 10 µM mutant ((D)3hIAPP), and 10 µM 
mutant ((isoD)3hIAPP) solution were acquired on a Jeol 2010F TEM operated at 200 
kV.  10 µL of incubated solution was transferred onto a carbon-coated grid and settled 
for one minute, followed by removing the excess solution using filter paper. A 2% (w/v) 
uranyl acetate solution was used for the negative stain. Multiple images with 
magnification from x10,000 to x40,000 were acquired.  
 
Thioflavin T (ThT) fluorescence reactivity.  The fluorescence reactivity of the 10 
µM hIAPP, mutant ((D)3hIAPP), mutant ((isoD)3hIAPP), and hIAPP seeding solutions 
were measured using a GloMax®-Multi Detection System (Promega; Wisconsin, USA).  
All samples were placed in a black 96 well-plate and mixed with 10 µM ThT aqueous 
solution.  Fluorescence spectra of the samples were acquired every 45 minutes with 
excitation at 405 nm and emission measurement at 490 nm, in a similar fashion to Chan 
et al.34, 35  The intensities obtained from the fluorescence spectrometer were 
normalized to the signal intensity of the most mature fibril. 
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Figure S1. Sequences of synthetic mutant hIAPPs. Asn residues at position 21, 22, and 
35 are replaced with aspartic acid – deamidated ((D)3hIAPP) or iso-aspartic acid – 
deamidated ((isoD)3hIAPP) in order to act as deamidation mimics. 
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Figure S2.  (A) Summary of  a-, c-, y-, and z-ion fragments observed in the (B) ECD 
MS/MS spectrum of the 7+ charge state ((D)3hIAPP) dimer.  Highlighted sequence 
represents the proposed non-covalent interaction region.  The side chain losses were 
not labeled for clarity.  The assigned fragments are listed in the ESI Table S1. 
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Table S1.  List of the assigned fragments from the ECD MS/MS spectrum of the 7+ 
charge state ((D)3hIAPP) dimer ion.  M represents one ((D)3hIAPP) unit. 
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Figure S3.  (A) Summary of  a-, c-, y-, and z-ion fragments observed in the (B) ECD 
MS/MS spectrum of the 7+ charge state ((isoD)3hIAPP) dimer.  Highlighted sequence 
represents the proposed non-covalent interaction region. The side chain losses were not 
labeled for clarity.  The assigned fragments are listed in the ESI Table S2. 
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Table S2.  List of the assigned fragments from the ECD MS/MS spectrum of the 7+ 
charge state ((isoD)3hIAPP) dimer ion.  M represents one ((isoD)3hIAPP) unit. 
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Figure S4.  The nESI-MS spectra showing the fresh, the incubated solutions, and the 
incubated fibrillary pellets of hIAPP mixed with 5%, 10%, 25%, or 50% of mutant 
((D)3hIAPP) or ((isoD)3hIAPP). 
 
